Hansa Biopharma AB (HNSBF)
2.93
0.00 (0.00%)
USD |
OTCM |
Sep 20, 16:00
Hansa Biopharma Revenue (Quarterly): 3.219M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 3.219M |
| March 31, 2024 | 5.398M |
| December 31, 2023 | 4.748M |
| September 30, 2023 | 2.117M |
| June 30, 2023 | 3.488M |
| March 31, 2023 | 2.321M |
| December 31, 2022 | 2.880M |
| September 30, 2022 | 6.398M |
| June 30, 2022 | 2.698M |
| March 31, 2022 | 3.250M |
| December 31, 2021 | 1.744M |
| September 30, 2021 | 0.5727M |
| June 30, 2021 | 0.5395M |
| March 31, 2021 | 1.075M |
| December 31, 2020 | 0.4452M |
| September 30, 2020 | 0.0861M |
| June 30, 2020 | 0.0644M |
| March 31, 2020 | 0.092M |
| December 31, 2019 | 0.1253M |
| September 30, 2019 | 0.068M |
| June 30, 2019 | 0.0627M |
| Date | Value |
|---|---|
| March 31, 2019 | 0.1001M |
| December 31, 2018 | 0.1532M |
| September 30, 2018 | 0.0541M |
| June 30, 2018 | 0.104M |
| March 31, 2018 | 0.0726M |
| December 31, 2017 | 0.1217M |
| September 30, 2017 | 0.0834M |
| June 30, 2017 | 0.0787M |
| March 31, 2017 | 0.1186M |
| December 31, 2016 | 0.0601M |
| September 30, 2016 | 0.1065M |
| June 30, 2016 | 0.066M |
| March 31, 2016 | 0.0695M |
| December 31, 2015 | 0.2082M |
| September 30, 2015 | 0.0623M |
| June 30, 2015 | 0.0628M |
| March 31, 2015 | 0.4626M |
| December 31, 2014 | 0.0211M |
| September 30, 2014 | |
| June 30, 2014 | 0.0529M |
| March 31, 2014 | 0.2495M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0644M
Minimum
Jun 2020
6.398M
Maximum
Sep 2022
2.066M
Average
1.930M
Median
Revenue (Quarterly) Benchmarks
| Abliva AB | -- |
| Karolinska Development AB | 0.0457M |
| Calliditas Therapeutics AB | 52.48M |
| Oncopeptides AB | 0.26M |
| BioInvent International AB | 0.4323M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.49M |
| Total Expenses (Quarterly) | 20.79M |
| EPS Diluted (Quarterly) | -0.3094 |
| Enterprise Value | 222.22M |
| Gross Profit Margin (Quarterly) | -18.04% |
| Profit Margin (Quarterly) | -605.6% |
| Earnings Yield | -46.86% |
| Normalized Earnings Yield | -46.86 |